SCHEMBL24310347

SCHEMBL24310347

Cc1cccc(C)c1-c1cc(Oc2ccccc2)nc(NSc2cnn(C)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR39 O43194 1/20 0.39
▸ CYP1A2 P05177 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ FYN P06241 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ NUDT1 P36639 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TNK2 Q07912 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ HPGD P15428 2/20 0.32
▸ L3MBTL1 Q9Y468 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310563 0.91 HPGD (0.31) GPR39MAPTHPGD
SCHEMBL24309575 0.90 NPC1 (0.33) MAPTMEN1KMT2AHTTMAPK1
SCHEMBL24310126 0.90 AURKA (0.36) ALDH1A1AURKAAURKBLMNA
SCHEMBL24309553 0.90 MAP4K1 (0.31) —
SCHEMBL24310142 0.90 GPR39 (0.30) GPR39
SCHEMBL24309688 0.88 MAPK1 (0.46) GPR39CYP1A2MAPTCYP2C9CYP2C19
SCHEMBL24310557 0.87 DGAT2 (0.32) —
SCHEMBL24309518 0.87 LMNA (0.39) MEN1KMT2AHTTNUDT1LMNA
SCHEMBL24309556 0.86 MAP4K1 (0.35) —
SCHEMBL24310009 0.86 GPR39 (0.45) GPR39CYP1A2MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback